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Previously, it has been reported that hypoxia causes increased mutagenesis and alteration in DNA repair mechanisms. In 2005, an
interesting study showed that hypoxia-induced decreases in BRCA1 expression and the consequent suppression of homologous
recombination may lead to genetic instability. However, nothing is yet known about the involvement of BRCA2 in hypoxic
conditions in breast cancer. Initially, a cell proliferation assay allowed us to hypothesize that hypoxia could negatively regulate the
breast cancer cell growth in short term in vitro studies. Subsequently, we analyzed gene expression in breast cancer cell lines exposed
to hypoxic condition bymicroarray analysis. Interestingly, genes involved inDNAdamage repair pathways such asmismatch repair,
nucleotide excision repair, nonhomologous end-joining and homologous recombination repair were downregulated. In particular,
we focused on the BRCA2 downregulation which was confirmed at mRNA and protein level. In addition, breast cancer cells were
treatedwith dimethyloxalylglycine (DMOG), a cell-permeable inhibitor of both proline and asparaginyl hydroxylases able to induce
HIF-1𝛼 stabilization in normoxia, providing results comparable to those previously described. These findings may provide new
insights into themechanisms underlying genetic instabilitymediated by hypoxia and BRCA involvement in sporadic breast cancers.
1. Introduction
Breast cancer (BC) is one of the leading causes of cancer-
related death among women worldwide [1]. About 5–10% of
familial breast cancers can be attributed to two autosomal
dominant genes with high penetrance: BRCA1 and BRCA2
[2]. Carriers of germline mutations in BRCA1 and BRCA2
have a predisposition for developing breast and/or ovarian
cancer [3]. In addition, it has been reported that BRCA1
expression was reduced or undetectable in the majority of
high-grade, ductal carcinomas, suggesting that absence of
BRCA1 may contribute to the pathogenesis of a significant
percentage of sporadic breast cancers [4, 5]. BRCA plays
an important role in DNA repair, activation of cell-cycle
checkpoints, andmaintenance of chromosome stability [6, 7].
In the last years, several authors reported that the tumor
microenvironment can contribute to genetic instability and
alter the overall DNA repair [8–14].
Mammalian cells are extremely intolerant to prolonged
exposure to hypoxia; contrariwise tumor cells are tolerant to
anoxia and many tumors contain hypoxic regions [15, 16].
Intratumoral hypoxia is an adverse clinical prognostic factor
associated with decreased disease-free survival for many
cancers such as the prostate, cervix, breast, and head and neck
[17–19]. Hypoxic tumor cells can be locally and systematically
aggressive with a decreased sensitivity to apoptotic and other
cell death signals, increased angiogenesis, increased prolifer-
ation, and increased capacity for systemic metastasis [20, 21].
It is now well known that hypoxia causes the stabilization
of HIF-1𝛼 monomer that translocates to the nucleus where
it heterodimerizes with HIF-1𝛽 and HIF-1 complex binds
to the hypoxia responsive element (HRE) on the promoter
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regions of target genes in order to promote tumor survival,
invasion, andmetastasis [22–25]. Recently, it has been shown
that under severe hypoxia conditions the mismatch repair
(MMR) genes, MLH1 andMSH2, are downregulated in p53-
and HIF-1a-dependent way in many tumor cell lines, thus
inducing genetic instability [10, 26]. Furthermore, Mihaylova
et al. reported that cells exposed to hypoxia- and low pHwere
found to have a diminished capacity for DNA repair com-
pared with controls [26]. In 2005, an important study showed
that hypoxia-induced decreases in BRCA1 expression and the
consequent suppression of homologous recombination may
lead to genetic instability [27]. However, nothing is yet known
about the involvement of BRCA2 in hypoxic conditions in
breast cancer.
Here, we aim to analyze gene expression in breast cancer
cell lines exposed to hypoxic condition with a focus on genes
involved in DNA damage repair (DDR), especially BRCA2.
2. Materials and Methods
2.1. Cell Cultures. Human BC cell lines, MCF-7, MDA-
MB-231, and SKBr3, purchased from the American Type
Culture Collection (Rockville, MD, USA), were cultured in
Dulbecco’s Modified Eagle Medium (DMEM : F12) supple-
mented with 10% fetal bovine serum (FBS) and antibiotics
(100U/mL penicillin and 50mg/mL streptomycin) (Invitro-
gen, Carlsbad, CA, USA). Eighty percent of confluent cell
lines were cultured in normoxic atmosphere of 16% O
2
, 79%
N
2
, and 5% CO
2
(by volume) for 24 h. Then medium was
changed and cells were further cultured under normoxia
or hypoxia (3% O
2
, 87% N
2
, 5% CO
2
, by volume) at two
different time-points, 24 h and 48 h. Furthermore, cells were
incubated in the absence (normoxia) or presence (hypoxia) of
HIF hydroxylase inhibitor, dimethyloxalylglycine (DMOG)
(Sigma-Aldrich, St. Louis, MO, USA), for 24 h and 48 h, at
final concentration of 1mM.
2.2. Cell Proliferation Assay. To analyze cell proliferative
activity, a 5-bromo-2󸀠-deoxyuridine (BrdU) assay was per-
formed using BrdU Cell Proliferation Assay Kit according
to the manufacturer’s instructions (Cell Signaling Technol-
ogy, Euroclone, Milano, Italy). Cells were seeded at 1 ×
10
4 cells/well in a 96-well plate and incubated overnight. To
assess proliferative activity under hypoxia, cells were directly
incubated under normoxia and hypoxia (for 24, 48, 72, and
96 hours). Ten 𝜇MBrdU was added to the plate, and the cells
were incubated for 4 hours. The absorbance at a wavelength
of 450 nm was measured using an ELISA microplate reader.
All experiments were performed in triplicate.
2.3. Microarray Analysis. Microarray analysis was performed
as previously described [28]. Total RNA was extracted
according to the manufacturer’s protocol (Affymetrix, Santa
Clara, CA, USA). Fragmented cRNA was hybridized using
a human oligonucleotide array U133 Plus 2.0 (Genechip
Affymetrix, Santa Clara, CA, USA). Washing and stain-
ing were performed through Affymetrix GeneChip Fluidic
Station 450. Probe arrays were scanned using Affymetrix
GeneChipScanner3000 G7enabled for high-resolution scan-
ning. Two biological replicates were performed for each
experimental condition. Images were extracted with the
GeneChip Operating Software (Affymetrix GCOS v1.4).
Quality control of the arrays was performed using the
AffyQCReport software [29].
2.4. Statistical Analysis. For statistical analysis, the back-
ground subtraction and normalization of probe set intensities
were performed using themethod of robustmultiarray analy-
sis (RMA) described by Irizarry et al. [30]. To identify DEGs,
gene expression intensity was compared using a moderated
𝑡-test and a Bayes smoothing approach developed for a low
number of replicates [31]. To correct for the effect of multiple
testing, the false discovery rate was estimated from 𝑃 values
derived from the moderated 𝑡-test statistics [32].The analysis
was performed using the affylmGUIGraphical User Interface
for the limma microarray package (Bioconductor Software)
[33]. Significant differences were determined by Student’s 𝑡-
test. 𝑃 value <0.05 was considered to be statistically signifi-
cant.
2.5. Microarray Data Analysis. Hierarchical cluster and heat
map analyses (HCA) were performed using the MultiExper-
iment Viewer (MeV v4.8) program of TM4 Microarray Soft-
ware Suite. Gene Set Analysis Toolkit was used to investigate
the biological significance of a set of genes represented by the
specific expression pattern inDNArepairmechanisms.DEGs
were analyzed according to predefined pathways annotated
by KEGG [34] and Biocarta bioinformatic resources. For an
overrepresented KEGG or Biocarta pathway, a cut-off𝑃 value
of 0.01 was selected. All showed values are in logarithm scale.
2.6. Quantitative Real-Time PCR (qRT-PCR) and RT-PCR.
Total cellular RNA was extracted using RNeasy Mini Kit
(Qiagen Inc., Valencia, CA, USA).Then, RNAwas controlled
through 2100 Bioanalyzer (Agilent Technologies, Santa Clara,
CA, USA) and quantified through the spectrophotometer
NanoDrop ND-1000 (CELBIO). For BRCA1, BRCA2, and
MLH1 mRNAs detection, 2 ng of total RNA was reverse
transcribed into single-stranded cDNA using High Capacity
cDNAReverse Transcription Kit (Applied Biosystems, Foster
City, CA, USA) according to vendor’s instructions. Gene-
primers for BRCA1, BRCA2, and MLH1 were purchased
from Applied Biosystems (TaqMan gene expression assay).
Quantitative real-time PCR (qRT-PCR) was performed with
the ABI PRISM 7900 sequence detection system (Applied
Biosystems, Foster City, CA, USA) using SDS software ver-
sion 2.1. The reactions were performed in triplicate and the
results were normalized using Human 𝛽-actin Predeveloped
TaqMan assay reagents (Applied Biosystems). Changes in the
target mRNA content were determined using a comparative
CT method (ABI User Bulletin number 2). An average CT
value for each RNA was obtained for triplicate reactions.
2.7. Western Blotting (WB). Cells were lysed using complete
Lysis-M reagent set (Roche, Mannheim, Germany). Protein
concentration was measured using Quick Start Bradford
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Figure 1: Role of hypoxia in cell proliferation. Cell proliferative activity was evaluated by BrdU incorporation assay. Data represent means of
different culture experiments, each performed in triplicate and are presented as fold changes ± SD. Cell proliferative activity at time 0 was set
to 1. MCF-7 (a), SKBr3 (b), and MDA-MB-231 (c) cell lines were cultured under normoxia or hypoxia for 24, 48, 72, and 96 hours.
(Bio-Rad Laboratories, Hercules, CA, USA). 80–100mg of
total protein lysate was separated on 10% polyacrylamide
gel under denaturing conditions and immunoblotted into
nitrocellulose membrane. The following antibodies (Abs)
were used: anti-BCRA2 goat (Santa Cruz Biotechnology,
Santa Cruz, CA, USA); anti-GAPDH(6C5) (Santa Cruz
Biotechnology, Santa Cruz, CA, USA); anti-HIF-1a rabbit
(Bethyl Laboratories, Montgomery, USA).
3. Results
3.1. Effects of Hypoxia on Cell Proliferation. To analyze the
effects of hypoxia on cell proliferation, a BrdU incorporation
assay was performed and proliferative activity was evaluated
in BC cells incubated under normoxia and hypoxia at
different times. Evaluation of BrdU incorporation percentage
showed that hypoxia reduces cell proliferation in MCF-7,
SKBr3, and MDA-MB-231 cells (Figure 1). It is interesting
to note that hypoxia appears to have a greater effect on
proliferation in the first 48 hours. The percentage increase,
in fact, after 48 hours appears to be comparable in both
conditions (normoxia and hypoxia) in all BC cell lines.
3.2. Gene Expression Profiling in Breast Cancer Cells under
Hypoxia. Since hypoxia is a condition which during tumor
growth influences the expression of several genes involved
in angiogenesis, proliferation, cell cycle control, and DNA
damage repair (DDR) mechanisms, we first performed a
microarray analysis, using Affymetrix platform, in order
to compare differential gene expression profiles in MCF-7,
MDA-MB-231, and SKBr3 human breast cancer cell lines
in response to hypoxic exposure for 24 and 48 hours,
respectively. This work was carried out in order to evaluate
the involvement of some genes inmolecular pathways related
to tumor pathogenesis. This analysis has allowed to obtain,
for each examined BC cell line, two lists of differentially
expressed genes (DEGs) in hypoxia for 24 and 48 hours
compared to normoxia (control). In particular, for this study,
the lists were screened considering as significant only the
genes with fold change (𝑀) > |0.5| (logarithm scale) and
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𝑃 < 0.05. Thus, we obtained six lists of DEGs with respect
to normoxia, including, after 24 h of hypoxia, 10,437 genes
(5,958 downregulated and 4,479 upregulated) for MCF-7;
11,267 genes (6,801 downregulated and 4,466 upregulated)
for MDA-MB-231; and 14,280 genes (8,450 downregulated
and 5,830 upregulated) for SKBr3; and, after 48 h of hypoxia,
11,205 genes (5,955 downregulated and 5,250 upregulated)
for MCF-7; 12,756 genes (5,656 downregulated and 7,100
upregulated) for MDA-MB-231; and 17.098 genes (9,180
downregulated and 7,918 upregulated) for SKBr3.
Then, six lists of geneswere comparedwith each other and
analyzed in order to identify a set of DEGs common to three
BC cell lines. Using Venn diagrams, we found 270 shared
genes (81 downregulated and 189 upregulated) that showed
a gene expression variation in hypoxia (24 h and 48 h) with
respect to normoxia.
3.3. Molecular Pathways Deregulated in Hypoxia. A further
series of studies was carried out on the microarray analysis
data in order to identify any genes of particular interest.
Significant gene expression variations were detected in genes
involved in angiogenesis, proliferation, cell cycle progression,
mitosis, genomic stability, and response to hypoxia.The inte-
grated analysis resulting from KEGG and Biocarta databases
allowed us to identify the main molecular pathways altered
in BC cell lines after hypoxic exposure for 24 h and 48 h.
This analysis indicated that the genes showing a significant
variation in expression levels are included in the following
pathways: DNA damage repair (37 genes), cell cycle regula-
tion (35 genes), HIF-1𝛼 network (15 genes), and mitosis reg-
ulation (12 genes). A considerable number of genes involved
in proliferation and cell cycle control, through the G1/S and
G2/M transitions, showed a significantly deregulated expres-
sion in all three BC cell lines. Among the DEGs in hypoxia,
required for G1/S transition, CDC6, CCND1, CCNE2, and
CDK2 were downregulated, whereas CDKN1A (p21Cip1) was
upregulated. Instead, CDC25A was downregulated in MCF-
7 and SKBr3 cells and upregulated in MDA-MB-231 cells.
Moreover, we found that in MCF-7 and SKBr3 cells hypoxia
induces downregulation of several genes required for G2/M
transition, such as CCNA2, CCNB1, CCNB2, CDC2 (CDK1),
and CDC25C.The same results were shown byMDA-MB-231
cells under hypoxic conditions for 24 h.
In addition, significant increases in expression levels were
also observed in key genes involved in HIF-1𝛼 network
(Figure 2(b)), such as VEGF-A, SLC2A1, JUN, FOS, and
other genes encoding for glycolytic enzymes (PGK1, PFKFB3,
HK2, and ALDOA). Finally, microarray analysis showed a
significant variation in expression levels of some genes that
regulate the mitosis included in AURKA signaling pathway.
Other genes involved in this pathway, such as AURKB, JUB
(ajuba), andTPX2, are downregulated in all three BC cell lines
under hypoxic conditions.
However, since several studies reported that the hypoxia
of tumor microenvironment can contribute to genetic insta-
bility [35], our attention was focused mainly on the DEGs
involved in DNA damage repair (DDR) pathways: mismatch
repair (MMR), nucleotide excision repair (NER), nonhomol-
ogous end-joining (NHEJ), and homologous recombination
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Figure 2: Heat maps of DEGs involved in DNA damage repair
(DDR) pathways deregulated in hypoxia. Clustering of DEGs
involved in DNA damage repair (DDR) pathways: mismatch repair
(MMR), nucleotide excision repair (NER), nonhomologous end-
joining (NHEJ), and homologous recombination repair (HRR).The
heat maps were generated from microarray data reflecting gene
expression values inMCF-7,MDA-MB-231, and SKBr3 cells exposed
to hypoxia (3% O
2
) for 24 h and 48 h in comparison to control
cells cultured under normoxic conditions (16% O
2
, 𝑀 > |1| and
𝑃 < 0.05). Each row represents the expression levels for a single gene
tested for different experimental conditions. Each column shows
the expression levels for the genes tested for a single experimental
condition. The absolute expression value (log scale) of each gene
is derived from the mean of two biological replicates. The color
scale bar on the top represents signal intensity variations ranging
fromgreen (poorly expressed genes) to red (highly expressed genes).
Black boxes indicate intermediate expression values. N = normoxia;
H24 = hypoxia for 24 h; H48 = hypoxia for 48 h.
repair (HRR) (Figure 2). In general, the expression of genes
involved in these pathways was found downregulated (see
Table S1 in Supplementary Material available online at
http://dx.doi.org/10.1155/2013/746858). The most significant
changes were observed in the HRR pathway. In particular,
in HRR we observed a significant decrease in expression
levels of BRCA1, BRCA2, RAD51, and RAD50. Furthermore,
there were significant variations in key genes involved in
MMR. In particular, we found a significant decrease in the
expression levels ofMLH1,MSH2, andMSH6. Moreover, we
demonstrated a more global effect on DNA damage repair
pathways as a result of the hypoxic exposure.
3.4. Downregulation of BRCA2 Expression under Hypoxia. In
order to validate microarray analysis data, we have evaluated
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Figure 3: Effects of hypoxia on BRCA2 expression in breast cancer cell lines. Validation of microarray data by quantitative real-time PCR
analysis. Changes in BRCA1 (a), BRCA2 (b), and MLH1 (c) mRNA expression levels were determined in MCF-7, SKBr3, and MDA-MB-231
cells exposed to hypoxia (3% O
2
) for 24 and 48 hours with respect to control condition (normoxia, 16% O
2
). Relative transcript levels were
determined using the 2−ΔΔCt method and normalized to 𝛽-actin mRNA (endogenous control). Normoxic condition values are taken as 1 and
hypoxic condition values represent fold decrease relative to control condition. Data are presented as fold changes ± SDs. Significant difference,
hypoxia for 24 h (H24) or for 48 h (H48) versus normoxia (N), ∗𝑃 < 0.05.
the BRCA2 mRNA expression levels in the same BC cell
lines under hypoxic conditions, using qRT-PCR. Moreover,
we assessed BRCA1 andMLH1mRNA expression levels, also
involved in DNA repair and for which a downregulation
in BC cell lines under hypoxic conditions has been already
observed. The qRT-PCR analysis confirmed that hypoxia
induces BRCA2 downregulation in all three BC cell lines
used. In particular, BRCA2 downregulation was more pro-
nounced in MDA-MB-231 cells (0.1-fold in both conditions);
in MCF-7 cells the reduction was 0.4-fold after 24 h of
hypoxia and 0.3-fold after 48 h of hypoxia exposure. These
results are comparable to those obtained in SKBr3 cells (0.3-
fold at 24 h, 0.2-fold at 48 h) (Figure 3(b)). As previously
reported, we also observed a downregulation of BRCA1 and
MLH1 mRNA levels under hypoxic conditions (Figures 3(a)
and 3(c)). In particular,BRCA1was 0.2-fold, 0.4-fold, and 0.3-
fold after 24 hours of hypoxia in MCF-7, SKBr3, and MDA-
MB-231, respectively, and 0.4-fold, 0.4-fold, and 0.2-fold after
48 hours of hypoxia in MCF-7, SKBr3, and MDA-MB-231,
respectively (Figure 3(a)). MLH1 was 0.4-fold, 0.8-fold, and
0.5-fold after 24 hours of hypoxia in MCF-7, SKBr3, and
MDA-MB-231, respectively, and 0.5-fold, 0.75-fold, and 0.6-
fold after 48 hours of hypoxia in MCF-7, SKBr3, and MDA-
MB-231, respectively (Figure 3(c)).
Interestingly, in parallel to BRCA2 mRNA downregu-
lation, we observed, through western blot (WB) analysis,
a reduction of BRCA2 protein levels in MCF-7, SKBr3,
and MDA-MB-231 cells after 24 h and 48 h of hypoxia,
compared to control condition (normoxia) (Figure 4). HIF-
1𝛼 protein levels were also evaluated. At the same time,
BC cells were treated with dimethyloxalylglycine (DMOG),
a cell-permeable inhibitor of both proline and asparaginyl
hydroxylases able to induceHIF-1a stabilization in normoxia.
Thus, treatment of MCF-7, MDA-MB-231, and SKBr3 cells
with a PHD inhibitor (for 24 h and 48 h) caused the activation
of the HIF-1 pathway in normoxia. In fact, WB analysis
provided results comparable to those previously described,
leading to an increase in HIF-1𝛼 expression levels and
concomitant reduction of BRCA2 expression in presence of
DMOG (Figure 4). Taken together these data suggest that
hypoxia could be the main reason for BRCA2 downregula-
tion.
4. Discussion
Breast cancer is the most common malignancy of the
mammary gland and its incidence increases with age.
Nowadays, although oncologists have several available
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Figure 4: Effects of hypoxia on BRCA2 and HIF-1𝛼 protein
expression levels in MCF-7, SKBr3, and MDA-MB-231 cells. Protein
expression was examined by western blot analysis with the indicated
antibodies, using the enhanced chemiluminescence reagent (ECL).
The GAPDH house-keeping protein was used as loading control
(N = normoxia; H24 = hypoxia for 24 h; H48 = hypoxia for 48 h).
The experimentswere performed at least three different times.MCF-
7, SKBr3 and MDA-MB-231 cells were also incubated with 1mM
DMOG for 24 h (H24) and 48 h (H48).
options (chemotherapy, hormone therapy, and biologic
agents such as antiangiogenic and anti-HER2 drugs), BC is
still responsible for a significant percentage of cancer deaths
in women [1, 36]. 80–85% of breast cancer is sporadic, while
15–20% shows a familial history. About 5–10% of cancers
can be attributed to two autosomal dominant genes with
high penetrance: BRCA1 and BRCA2. BRCA2 is a protein
of about 3000 amino acids, which can bind directly to
DNA, by helix-loop-helix domain. This protein is important
with BRCA1 in homologous recombination repair (HRR)
mechanism of double-strand DNA breaks. BRCA2 interacts
directly with RAD51 at the C-terminal region and seems to
be also involved in its transport to the nucleus.
Hypoxia is a typical feature of microenvironment of
several solid tumors and is associated with poor prognosis
in several cancer types, including BC [37]. Under conditions
of severe hypoxia, several cancer cell lines exhibit genetic
instability showing downregulation of MLH1 and MSH2
expressions in a p53- and HIF-1𝛼-dependent manner. Since
tumor hypoxia is known to be an important factor for the
expression of many genes involved in tumorigenesis, cell
cycle regulation, and genetic instability [38], we performed
a microarray-based gene expression analysis in order to
determine different expression profiles inMCF-7, MDA-MB-
231, and SKBr3 BC cells in response to hypoxia for 24 h and
48 h, respectively. In addition, cell proliferation assays by
BrdU allowed us to hypothesize that hypoxia could negatively
regulate the BC cell growth in short term in vitro studies.This
microarray study allowed us to identify a set of 270 DEGs
in hypoxia (81 downregulated and 189 upregulated) common
to three BC cell lines (fold change > |0.5| and 𝑃 < 0.05).
Our attention was focused mainly on the genes showing a
significant variation in expression levels involved in prolif-
eration, cell cycle progression and regulation, mitosis, DDR
mechanisms, and response to hypoxia. After hypoxia for
24 h and 48 h, the following main molecular pathways were
found altered in BC cell lines: DNA damage repair, cell cycle
regulation, HIF-1𝛼 network, and mitosis control. Among
the DEGs involved in proliferation and cell cycle control,
CDKN1A (p21Cip1), that can elicit the G1/S checkpoint, was
upregulated, while genes that further determine entry from
G1 to S-phase, including CDC6, CCND1, CCNE2, and CDK2,
were decreased in expression. Concomitant with decreased
G1 to S-phase progression, a reduced expression of genes
that regulate the passage of cells through G2/M, including
CCNA2, CCNB1, CCNB2, CDC2 (CDK1), and CDC25C, was
also found in MCF-7 and SKBr3 cells exposed to hypoxia
for 24 h and 48 h and in MDA-MB-231 cells under hypoxia
for 24 h. In addition, among the DEGs involved in HIF-
1a network, VEGF-A, SLC2A1, JUN, FOS, and other genes
encoding for glycolytic enzymes (PGK1, PFKFB3, HK2, and
ALDOA) were upregulated in all three analyzed BC cell lines.
Finally, microarray analysis showed a significant downregu-
lation of expression of the DEGs involved in DNA damage
repair (DDR) pathways: mismatch repair (MMR), nucleotide
excision repair (NER), nonhomologous end-joining (NHEJ),
and homologous recombination repair (HRR). The most
significant gene expression variations were observed in the
HRR pathway. In particular, in HRR we found a significant
decrease in expression levels of BRCA1, BRCA2, RAD51 and
RAD50. Also, other genes involved inMMRmechanismwere
found downregulated (MLH1,MSH2, andMSH6).
In a previous work, Meng et al. reported that hypoxia
downregulates the expression of DNA double-strand break
(DNA-dsb) repair genes involved in HHR mechanism,
including BRCA1 and BRCA2, in prostate cancer cell lines
[39].
For the first time, our microarray study showed that
hypoxia induces a noteworthy downregulation of BRCA2
expression that could involve an important pathophysiologi-
cal role in BC. Quantitative real-time PCR and western blot
analyses confirmed microarray results. BRCA2 downregu-
lation by hypoxia may represent an interesting mechanism
of functional BRCA inactivation in the absence of genetic
mutations.
5. Conclusions
Since BRCA2 is an important regulator of homologous
recombination process in mammalian cells, its downregula-
tion could play a critical role inDNAdamage repair providing
innovative approaches for the development of novel possible
therapeutic strategies against BC. These findings may pro-
vide new insights into the mechanisms underlying genetic
instability mediated by hypoxia and BRCA involvement in
sporadic breast cancers. However, further studies will be
needed to better understand the mechanisms underlying the
hypoxia-induced BRCA downregulation.
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